Share on StockTwits

Shares of Omnicare (NYSE:OCR) have been given a consensus recommendation of “Buy” by the seven analysts that are covering the stock, Stock Ratings News reports. One analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $67.00.

Separately, analysts at Bank of America reiterated a “buy” rating on shares of Omnicare in a research note on Friday. They now have a $73.00 price target on the stock, up previously from $69.00.

Shares of Omnicare (NYSE:OCR) traded up 0.38% on Friday, hitting $66.35. The stock had a trading volume of 183,077 shares. Omnicare has a 1-year low of $46.47 and a 1-year high of $67.01. The stock’s 50-day moving average is $63.27 and its 200-day moving average is $60.82. The company’s market cap is $6.570 billion.

Omnicare (NYSE:OCR) last announced its earnings results on Wednesday, April 23rd. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.01. The company had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.55 billion. During the same quarter in the previous year, the company posted $0.90 earnings per share. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. On average, analysts predict that Omnicare will post $3.69 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which is scheduled for Thursday, June 26th. Shareholders of record on Thursday, June 12th will be given a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 1.21%. The ex-dividend date of this dividend is Tuesday, June 10th.

Omnicare, Inc (NYSE:OCR) is a healthcare services company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.